A new in vivo proarrhythmia model of drug-induced long QT syndrome was developed using the Microminipig, an incredibly small minipig established by Fuji Micra Inc. (Shizuoka). The atrioventricular (AV) node of the Microminipig of either sex weighing approximately 6 -7 kg was ablated under halothane anesthesia, and proper care was taken for them. Proarrhythmic effects of drugs were assessed at >2 months after the onset of AV block using a Holter recording system. Oral administration of dl-sotalol (10 mg/kg) to the AV-block Microminipig prolonged the QT interval; moreover, it frequently induced dangerous ventricular premature beats, whereas no arrhythmia was detected after the vehicle administration (n = 4). Such dl-sotalol-induced ventricular arrhythmias were not detected in the intact Microminipig with sinus rhythm, although significant QT prolongation was observed (n = 4). Thus, the sensitivity and specificity of the AV-block Microminipig for detecting the drug-induced long QT syndrome can be considered to be comparable to previously established AV-block animal models of dogs and monkeys.
Introduction
A number of non-cardiac drugs as well as antiarrhythmic agents have been reported to prolong QT interval by inhibiting a rapid component of delayed rectifier K + currents (I Kr ) in the heart, occasionally causing torsades de pointes (TdP) in patients. When TdP is induced, it can lead to ventricular fibrillation and sudden cardiac death, which is considered to be an increasing public problem. However, these drugs did not show excessive QT-interval prolongation in the preclinical animal model with intact hearts or in the phase-1 clinical studies (1 -4). Moreover, the risk of QT-interval prolongation is compounded by various factors; namely, being female; heart disease including congenital long QT syndrome, myocardial in-farction, congestive heart failure, dilated cardiomyopathy, hypertrophic cardiomyopathy, and bradycardia; hypokalemia; and hepatic impairment (5). In recent years, there have been considerable advances in the assessment and understanding of ventricular repolarization and TdP, since cloning of cardiac ion channels has unraveled the role of ionic channels in mediating cardiac repolarization, the pathophysiological mechanism of long QT syndrome, and pathogenesis of TdP (6). Besides introducing these types of knowledge, in this review, we focused on recent advances in the in vivo proarrhythmia models of drug-induced long QT syndrome.
Role of reduced repolarization reserve and spatial and temporal dispersions of repolarization in the onset of drug-induced long QT syndrome
QT-interval prolongation by I Kr -channel blockers is thought to occur only in patients with reduced repolarization reserve (1). As summarized in Fig. 1 , there is more repolarization reserve in normal heart (left panels) than in sick heart (right panels), which may make the animal models with normal hearts less sensitive for detecting the drug-induced QT-interval prolongation (3, 4). Meanwhile, animal models having a limited repolarization reserve are considered to be most susceptible to druginduced QT-interval prolongation as depicted in Fig. 1 (right panels), which needs to be developed.
As summarized in Fig. 2 , the drug-induced excessive QT-interval prolongation usually consists of heterogeneous delay in phase 3 repolarization of ventricular action potential, which increases "spatial" dispersion of repolarization, enhancing electrical vulnerability of the ventricles (3, 7 -10). Also, I Kr -channel blockers increase beat-to-beat variability of repolarization besides QT-interval prolongation (11), enhancing "temporal" dispersion of repolarization, leading to onset of early afterdepolarizations and R on T type premature ventricular contractions (12), which trigger TdP in the presence of "spatial" dispersion (3, 7 -9).
In vivo proarrhythmia model of dogs
The chronic atrioventricular (AV) block dog has been widely used for the assessment of proarrhythmic effects of many drugs for >10 years, so, it is considered to be one of the most reliable in vivo models of proarrhythmia (3). On preparing this model, catheter ablation was used to produce AV conduction block, leading to a persistent bradycardia of 30 -40 bpm (13) . Previous studies have indicated that this model is associated with macroscopic and microscopic myocardial hypertrophy, increased collagen fiber and extracellular space, downregulation of I Ks channels, increased sympathetic drive promoting calcium overload, and elevation of plasma atrial natriuretic peptides and angiotensin II (7, 8, 13, 14) . The AV-block dogs with no pharmacological treatment usually survived for several years without TdP attack. Based on the results of pharmacologically treated animals, drugs that induced TdP at <1 -3 times the therapeutic dose were classified into the High-risk group; those that did not induce TdP at this dose, but induced it at higher doses belonged to Low-risk group; and those that never induced TdP at any dose tested were considered to be in the No-risk group (3). IKr-channel blockers are distributed to the heart based on their pharmacokinetic profile to prolong QT interval in patients with reduced repolarization reserve, which will provide temporal and spatial dispersions of repolarization, leading to the onset of TdP. According to the ICH S7B guideline (6), it has been recommended that the IKr inhibitory profile of a drug is examined by in vitro IKr assay, and druginduced QT-interval prolongation is assessed by in vivo QT assay, while drug-induced proarrhythmic substrates, triggers, and lethal arrhythmias are confirmed by follow-up studies. This figure was modified from ref. 3.
In vivo proarrhythmia model of monkeys
Since safety pharmacological analysis of new molecular entities was usually carried out using monkeys and/or dogs, we have developed chronic AV-block model of the monkey and characterized it as a model to examine torsadogenic action of drugs possessing I Kr -channel inhibitory property (3). The model has essentially the same pathophysiological adaptations and drug responses as those demonstrated in the canine model ( Table 1 ), except that >6 months were indispensable to fully accomplish the adaptation process and TdP often terminated spontaneously unlike in the dog model. Since few monkeys died during the drug study, it will be possible to compare the effects of multiple drugs using the same animal group.
New in vivo proarrhythmia model of pigs
Recently, an incredibly small minipig (Microminipig) weighing <10 kg was established by Fuji Micra Inc. (Shizuoka) (15) . Since dogs and monkeys may have some limitations related to animal welfare during experimental use, pigs are expected to become an alternative to the current in vivo models. The AV node of the Microminipig of either sex weighing approximately 6 -7 kg was ablated under halothane anesthesia as depicted in Fig. 3 , and proper care was taken for them. Proarrhythmic effects of drugs were assessed at >2 months after the onset of AV block using the Holter recording system. Oral administration of dl-sotalol (10 mg/kg, n = 4) prolonged the QT interval of the AV-block Microminipig. Also, it frequently induced dangerous ventricular premature beats, including R on T phenomenon and slow ventricular tachycardia, as depicted in Fig. 4 , whereas no arrhythmia was detected after the vehicle administration (n = 4). The plasma concentration of dl-sotalol determined by HPLC with fluorescence detection was 2.8 ± 0.3 μg/ml (mean ± S.E.M., n = 4) at 2 h after the administration. Since therapeutic plasma concentrations of dl-sotalol during repeated oral administration in humans have been reported to be 0.456 -3.647 μg/ml, the plasma drug concentrations in the present study may correspond to the therapeutic level (16) . Such dl-sotalolinduced ventricular premature beats were not detected in the intact Microminipig with sinus rhythm, although significant QT-interval prolongation was observed (n = 4), as depicted in Fig. 5 . Thus, the sensitivity and specificity of the AV-block Microminipig for detecting the drug-induced long QT syndrome can be comparable to previously established AV-block animal models of dogs and monkeys (Table 1) .
Conclusion
Drug-induced long QT syndrome is an increasing public health problem, in which blockade of the I Kr channel is responsible for its proarrhythmic effect. The in vivo proarrhythmia models described in this review can directly examine the risk of drugs for drug-induced lethal arrhythmias. With the use of the new in vivo animal models described in this review together with conventional in vitro assay technologies, including isolated cells, cell lines, and expression systems cloned for specific ion channels, it will be possible to identify and quantify the risk of proarrhythmia during the preclinical development of a drug. The example of the Microminipig ECG at pre-drug control. Note the atrioventricular conduction block was kept. B) ECG at 2 and 9 h after the administration of dl-sotalol. Note R on T phenomenon and slow ventricular tachycardia were recorded. C) Time-course of RR interval for 24 h. Note that the RR interval became irregular 30 min to 11 h after the administration of the drug because of frequent occurrence of premature ventricular contractions.
